Kernal Biologics develops mRNA-based therapeutics designed to instruct cells to produce their own medicines, particularly targeting areas within immuno-oncology. The company is advancing its proprietary mRNA 2.0 technology, which addresses challenges related to cancer cell selectivity inherent in current mRNA therapies and oncolytic virus treatments. Founded in the vibrant bioscience ecosystem of Cambridge, MA, Kernal Biologics brings together a team of experts with backgrounds from leading institutions like MIT and Harvard, as well as experience in both academia and the pharmaceutical industry. The organization values innovation, collaboration, and a commitment to addressing complex medical challenges through cutting-edge research and development in the life sciences.